RxSight, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 04:21 pm
Share
RxSight, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 22.2 million compared to USD 12.62 million a year ago. Net loss was USD 12.42 million compared to USD 16.82 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.61 a year ago.
For the nine months, sales was USD 60.5 million compared to USD 32.92 million a year ago. Net loss was USD 39.43 million compared to USD 51.15 million a year ago. Basic loss per share from continuing operations was USD 1.16 compared to USD 1.86 a year ago.
RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Companyâs RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patientâs vision outcomes.
RXSIGHT, INC. 
